mTOR Signaling Pathway in Antiphospholipid Syndrome: Pathogenesis and Potential Therapeutic Targets

Apr 8, 2026Drug design, development and therapy

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Activation of the may mediate immune disorders associated with (APS).

Antiphospholipid syndrome is characterized by thrombosis and persistent positive antiphospholipid antibodies.
The pathogenesis of APS may involve activation of vascular endothelial cells and immune cells.
Complement activation is also suggested to play a role in APS.
Previous studies indicate that mTOR is linked to pro-inflammatory and pro-coagulant processes.
Understanding the role of mTOR in APS could aid in identifying new therapeutic targets.

AI simplified

(APS) is an autoimmune disorder characterized by thrombosis in arteries, veins or small blood vessels, and/or obstetric APS (OAPS), as well as persistent positive antiphospholipid antibodies. In recent years, some authors have proposed that the pathogenesis of APS is closely related to activation of vascular endothelial cells, immune cells, and complement activation. However, further exploration is still needed. Previous studies have shown that the mammalian target of rapamycin (mTOR) is associated with pro-inflammatory and pro-coagulant processes. This indicates that the activation of the may function as an intermediate mediator, causing immune disorders, thereby leading to thrombosis and OAPS. Therefore, we should correctly understand the potential pathogenic role of the mTOR signaling pathway in APS, which will be more conducive to clinicians' understanding of the pathogenesis of this disease and the search for new therapeutic targets. We hope this can open up a new window for the management of APS.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (PDF) ↗

mTOR Signaling Pathway in Antiphospholipid Syndrome: Pathogenesis and Potential Therapeutic Targets

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief